Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'Benzinga • 04/07/25
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic FibrosisBusiness Wire • 04/07/25
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the StormThe Motley Fool • 04/06/25
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.The Motley Fool • 04/04/25
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksCNBC • 04/01/25
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline CandidatesZacks Investment Research • 04/01/25
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great RecessionThe Motley Fool • 03/28/25
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 03/27/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Market Pullback After a Historic Rally: What Investors Should Do NowZacks Investment Research • 03/21/25
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy PointInvestors Business Daily • 03/21/25
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 03/19/25
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does NextThe Motley Fool • 03/19/25